Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004329 · ClinicalTrials.gov registry record
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
A clinical trial, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- 12
- Enrollment target
NCT00004329: Completed study, sponsored by National Center for Research Resources (NCRR).
NCT00004329 is a clinical trial that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004329 has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls. II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1999-11 |
What the finished NCT00004329 record still lists
NCT00004329 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00004329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004329 about?
NCT00004329 is a clinical study titled "Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy". OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls. II. Determine the full sequence of the alpha-2 adr...
What is the current status of trial NCT00004329?
This trial is currently completed. The enrollment target is 12 participants. The study started on 1999-11.
Who is sponsoring clinical trial NCT00004329?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia